Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome

International Journal of Obesity volume 27, pages 862–865 (2003)Cite this article

Abstract

OBJECTIVE: We aimed to study the effect of atorvastatin, a statin, on cholesterol synthesis and absorption and VLDL-apoB metabolism in obese men with the metabolic syndrome.

METHODS: A total of 25 dyslipidaemic obese men were randomized to atorvastatin (n=13) (40 mg/day) or matching placebo (n=12) for 6 weeks. Hepatic secretion and fractional catabolic rate (FCR) of VLDL-apoB was measured using an intravenous bolus of d3-leucine before and after treatment. ApoB isotopic enrichment was measured using GCMS and multicompartmental modelling. Plasma lathosterol: cholesterol and campesterol:cholesterol ratios were determined to assess cholesterol synthesis and cholesterol absorption, respectively.

RESULTS: Compared with placebo, atorvastatin significantly decreased (P<0.05) total cholesterol, triglyceride, LDL-cholesterol and VLDL-apoB. Plasma lathosterol:cholesterol ratio decreased from 26.4±2.4 to 8.8±0.8, while the campesterol:cholesterol ratio increased from 26.5±4.4 to 38.6±5.8 (P<0.01). Atorvastatin also increased VLDL-apoB FCR from 3.82±0.33 to 6.30±0.75 pools/day (P<0.01), but did not significantly alter VLDL-apoB secretion (12.8±1.7 to 13.8±2.0 mg/kg/day).

CONCLUSIONS: In obesity, atorvastatin inhibits cholesterogenesis but increases intestinal cholesterol absorption. The increased cholesterol absorption may counteract the inhibitory effect on hepatic VLDL-apoB secretion, but it does not apparently influence enhanced catabolism of VLDL-apoB.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Ginsberg HN . Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453–458.

    Article  CAS  Google Scholar 

  2. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PHR . Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 2002; 51: 1041–1046.

    Article  CAS  Google Scholar 

  3. Thompson GR, Naoumova R, Watts GF . Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996; 37: 439–447.

    CAS  PubMed  Google Scholar 

  4. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PH . Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999; 84:2854–2861.

    CAS  Google Scholar 

  5. Simonen PP, Gylling H, Howard AN, Miettinen TA . Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 2000; 72: 82–88.

    Article  CAS  Google Scholar 

  6. Miettinen TA, Tilvis RS, Kesaniemi YA . Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990; 131: 20–31.

    Article  CAS  Google Scholar 

  7. Gylling H, Miettinen TA . Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res 1996; 37: 1776–1785.

    CAS  PubMed  Google Scholar 

  8. Simonen PP, Gylling H, Miettinen TA . Body weight modulates cholesterol metabolism in non-insulin dependent type 2 diabetics. Obes Res 2002; 10: 328–335.

    Article  CAS  Google Scholar 

  9. Watts GF, Naoumova RP, Kelly JM, Riches FM, Croft KD, Thompson GR . Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 1997; 273: 462–470.

    Google Scholar 

  10. Watts GF, Cummings MH, Umpleby M, Quiney JR, Naoumova R, Thompson GR . Sonksen PH. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur J Clin Invest 1995; 25: 559–567.

    Article  CAS  Google Scholar 

  11. Lindenthal B, Sudhop T, Schiedermaier P, Agnan M, Sauerbruch T, von Bergmann K . Serum plant sterols and biliary cholesterol secretion in humans: studies with ursodeoxycholic acid. J Lipid Res 2002; 43: 1072–1077.

    Article  CAS  Google Scholar 

  12. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL . Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988; 8:1147–1150.

    Article  CAS  Google Scholar 

  13. Vanhanen H, Kesäniemi YA, Miettinen TA . Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids and cholesterol absorption in man. Metabolism 1992; 41: 588–595.

    Article  CAS  Google Scholar 

  14. Duane WC . Effects of lovastatin and dietary cholesterol on sterol homeostasis in healthy human subjects. J Clin Invest 1993; 92: 911–918.

    Article  CAS  Google Scholar 

  15. Sehayek E, Ono JG, Shefer S, Nguyen LB, Wang N, Batta AK, Salen G, Smith JD, Tall AR, Breslow JL . Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci 1998; 95: 10194–10199.

    Article  CAS  Google Scholar 

  16. Ostlund RE, Bosner MS, Stenson WF . Cholesterol absorption efficiency declines at moderate dietary doses in normal human subjects. J Lipid Res 1999; 40: 1453–1458.

    CAS  PubMed  Google Scholar 

  17. Kesaniemi YA, Grundy SM . Overproduction of low density lipoproteins associated with coronary heart disease. Arteriosclerosis 1983; 3: 40–46.

    Article  CAS  Google Scholar 

  18. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP . Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955–1961.

    Article  CAS  Google Scholar 

  19. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP, Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001; 23: 1209–1230.

    Article  CAS  Google Scholar 

  20. Berge KE, von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC . Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res 2002 43: 486–494.

Download references

Acknowledgements

This study was supported by the National Heart Foundation of Australia, the National Health Medical Research Council of Australia, the Medical Research Foundation (Royal Perth Hospital), Pfizer Australia and the National Institutes of Health (NCRR 12609). PHRB is a Career Development Fellow of the National Heart Foundation.

Author information

Authors and Affiliations

  1. School of Medicine and Pharmacology, University of Western Australia, West Australian Institute for Medical Research, Royal Perth Hospital, Perth, W Australia

    G F Watts, D C Chan & P H R Barrett

  2. Division of Investigative Science, Department of Metabolic Medicine, Imperial College School of Medicine, University of London, UK

    F H O' Neill & G R Thompson

Authors
  1. G F Watts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D C Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P H R Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F H O' Neill
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G R Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G F Watts.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Watts, G., Chan, D., Barrett, P. et al. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes 27, 862–865 (2003). https://doi.org/10.1038/sj.ijo.0802287

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0802287

Keywords

This article is cited by

Search

Advanced search

Quick links